# A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

> **NCT03962647** · EARLY_PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** 2-Week Ketogenic Diet
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT03962647
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-08
- **Primary completion:** 2024-03-07
- **Final completion:** 2024-07-14
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962647, "A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03962647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*